ResMed Inc.
RMD
Positions held
Your positionsRMD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- ResMed Inc. operates in a growing healthcare sector focused on innovative medical instruments and supplies, positioning itself well against competitors.
- In 2026-Q2, ResMed reported revenue of $1.46 billion, reflecting a 2% increase from the previous quarter.
- The company achieved a profit margin of 26.9% and an operating margin of 30.7% in the same quarter.
- The operating margin has compressed from 34.9% in 2026-Q1 to 30.7% in 2026-Q2, indicating potential challenges in maintaining profitability.
- Gross margin decreased to 58.8% in 2026-Q2, down from 62.2% in the prior quarter.
- The current market sentiment is neutral with a score of 0.00, suggesting uncertainty in future performance.
Fundamentals
| Market cap | $31.89B | Enterprise value | $32.06B | Trailing P/E | 21.74 | Forward P/E | 17.14 |
| PEG | 1.31 | Price / book | 4.97 | Beta | 0.75 | Dividend yield | 1.16% |
| Revenue growth | 8.6% | Earnings growth | 2.4% | Gross margin | 61.6% | Operating margin | 30.9% |
| Profit margin | 26.9% | ROE | 24.3% | ROA | 14.0% | Debt / equity | 0.13 |
| Current ratio | 3.10 | Free cash flow | $939.25M | Analyst recommendation | buy | Mean target | $250.22 |
| 52w high | $277.85 | 52w low | $180.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.4B | $1.4B | $1.3B | $1.3B |
| Op margin | 30.7% | 34.9% | 35.0% | 34.6% | 33.9% |
| Net income | $383M | $399M | $393M | $349M | $380M |
| Gross margin | 58.8% | 62.2% | 61.8% | 61.5% | 60.8% |
| Gross profit | $861M | $891M | $879M | $821M | $820M |
| Operating income | $449M | $500M | $498M | $462M | $457M |
- Revenue +2% vs prior quarter ($1.5B vs $1.4B).
- Gross margin 58.8% (was 62.2% prior quarter).
- Operating margin compressed to 30.7%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $5.7B | $5.1B | $4.7B | $4.2B | — |
| Op margin | 33.8% | 32.7% | 29.5% | 27.3% | — |
| Net income | $1.5B | $1.4B | $1.0B | $898M | — |
| Gross margin | 61.1% | 59.4% | 56.7% | 55.8% | — |
| Gross profit | $3.5B | $3.1B | $2.7B | $2.4B | — |
| Operating income | $1.9B | $1.7B | $1.4B | $1.2B | — |
Headlines — positive tone
• [OK · fundamentals] Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
News
2026-10-08 · Resmed Insider Sold Shares Worth $1,129,637, According to a Recent SEC Filing
2026-10-05 · ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings?
2026-10-02 · 2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
2026-10-01 · Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
2026-09-28 · This Stock Could Be the Big Winner Out of Oura’s IPO
2026-09-28 · Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
2026-09-21 · ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
2026-09-19 · ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
2026-09-15 · Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
2026-09-15 · This Analyst Just Upgraded ResMed Stock. Here's Why.
2026-09-15 · Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
2026-09-15 · ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says
Price (daily)
Full chart · RSI · MACD · patterns